Newsroom
Sorted by: Latest
-
TÜV Rheinland North America Honors Teradyne with 2026 Excellence in Safety and Sustainability Leadership Award
BOXBOROUGH, Mass.--(BUSINESS WIRE)--TÜV Rheinland North America honors Teradyne with its 2026 Safety and Sustainability Leadership Award for excellence in safety and sustainability....
-
Cryomate Sperm Bank Opens Nashville Sperm Donation Center, Expanding Access to Diverse Donors and Advanced Genetic Screening
NASHVILLE, Tenn.--(BUSINESS WIRE)--Cryomate Sperm Bank opens its second U.S. location in Nashville, expanding access to diverse sperm donors backed by advanced genetic screening....
-
Capstone Energy+ to Present at the 20th Annual LD Micro Main Event
LOS ANGELES--(BUSINESS WIRE)--Capstone Energy+, Inc. (NASDAQ: CEPL) (“Capstone” or the “Company”), a leading provider of behind-the-meter clean microturbine energy solutions for industrial and commercial businesses, as well as solutions designed for emerging data center applications, today announced that members of its management team are scheduled to participate in the LD Micro 20th Annual Main Event, which is being held from October 19-21, 2026 in Los Angeles, CA. Date: October 20, 2026 Locat...
-
NATIXIS UK Regulatory Announcement: Form 8.3 Segro plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
NATIXIS UK Regulatory Announcement: Form 8.3 Prologis, Inc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
Roseburg Urban Sanitary Authority and Ameresco Celebrate Completion of Energy Infrastructure Project
FRAMINGHAM, Mass. & ROSEBURG, Ore.--(BUSINESS WIRE)--Solar-plus-storage system offsets 100 percent of RUSA's Main Office electricity use and strengthens power reliability for wastewater operations....
-
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) resubmission for tabelecleucel,...
-
Sensata Technologies Announces Brake Force Sensors Enabling Next-Generation Electromechanical Braking Systems in Production EVs
SWINDON, United Kingdom--(BUSINESS WIRE)--Sensata Technologies (NYSE: ST), today announced its brake force sensors are now enabling electromechanical braking (EMB) systems in leading electric vehicles. This milestone marks a significant step in the transition from traditional hydraulic braking to fully electric, brake-by-wire systems, as vehicle OEMs increasingly adopt architectures designed for electrification, autonomy, and software-defined control. Electromechanical brakes represent a shift...
-
Delve Bio Expands Metagenomic Infectious Disease Testing with Launch of Delve Detect Plasma at IDWeek 2026
BOSTON--(BUSINESS WIRE)--Delve Detect Plasma enables unbiased detection of more than 68,000 bacteria, fungi, DNA and RNA viruses, and parasites with next-day results...
-
Beacon Hospital Research Institute and B-Secur Launch Pilot to Bring ECG Data from Consumer Wearables Directly into Clinical Care
DUBLIN--(BUSINESS WIRE)--B-Secur and Beacon Hospital Research Institute launch clinical pilot to bring ECG data from any consumer wearable directly into the clinical workflow....